UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 20, 2014
INSMED INCORPORATED
(Exact name of registrant as specified in its charter)
|
Virginia |
|
0-30739 |
|
54-1972729 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(I.R.S. Employer Identification |
|
9 Deer Park Drive, Suite C, Monmouth Junction, New Jersey |
|
08852 |
|
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area code: (732) 997-4600
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On May 20, 2014, Insmed Incorporated (the “Company”) issued a press release announcing additional results from the Company’s Phase 2 Clinical Trial for the treatment of patients with treatment resistant nontuberculous mycobacterial lung infections.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Press Release dated May 20, 2014 titled “Insmed Announces Positive Open Label Data from Phase 2 Clinical Trial of ARIKAYCE for Treatment Resistant Nontuberculous Mycobacterial Lung Infections.” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Dated: May 20, 2014 |
INSMED INCORPORATED | |
|
|
By: |
/s/ Christine Pellizzari |
|
|
Name: |
Christine Pellizzari |
|
|
Title: |
General Counsel and |